Accelus closed a new equity financing round led by Concord Health Partners. The capital will support Accelus’s continued commercial growth and further development of its differentiated spinal implant technologies.
The additional funding will enable the company to expand its reach and continue building momentum as it expands its FlareHawk and Toro portfolios.
Accelus’s product portfolio includes the FlareHawk Interbody Fusion System featuring Adaptive Geometry technology, LineSider Spinal System with modular-cortical screws and Toro-L Interbody Fusion System. The company’s implants and instruments support minimally invasive techniques suitable for both hospital and ambulatory surgery center environments.
In conjunction with the financing, the company appointed industry veteran Bernie Haffey as Chairman of the Board of Directors. Mr. Haffey, who joined the Accelus board in February 2024, has over 20 years of medtech and healthcare sector experience and will help oversee the Company’s next phase of growth.
“The continued support from our partners through this latest equity financing round reinforces our long-term vision to bring meaningful innovation to spine care and expand access to minimally invasive solutions for both surgeons and patients,” said Kevin McGann, President and CEO of Accelus. “We are now well positioned to deepen our U.S. market presence and invest in future pipeline innovations that meet the real-world needs of spine surgeons across care settings.”
Accelus closed a new equity financing round led by Concord Health Partners. The capital will support Accelus’s continued commercial growth and further development of its differentiated spinal implant technologies.
The additional funding will enable the company to expand its reach and continue building momentum as it expands its FlareHawk and...
Accelus closed a new equity financing round led by Concord Health Partners. The capital will support Accelus’s continued commercial growth and further development of its differentiated spinal implant technologies.
The additional funding will enable the company to expand its reach and continue building momentum as it expands its FlareHawk and Toro portfolios.
Accelus’s product portfolio includes the FlareHawk Interbody Fusion System featuring Adaptive Geometry technology, LineSider Spinal System with modular-cortical screws and Toro-L Interbody Fusion System. The company’s implants and instruments support minimally invasive techniques suitable for both hospital and ambulatory surgery center environments.
In conjunction with the financing, the company appointed industry veteran Bernie Haffey as Chairman of the Board of Directors. Mr. Haffey, who joined the Accelus board in February 2024, has over 20 years of medtech and healthcare sector experience and will help oversee the Company’s next phase of growth.
“The continued support from our partners through this latest equity financing round reinforces our long-term vision to bring meaningful innovation to spine care and expand access to minimally invasive solutions for both surgeons and patients,” said Kevin McGann, President and CEO of Accelus. “We are now well positioned to deepen our U.S. market presence and invest in future pipeline innovations that meet the real-world needs of spine surgeons across care settings.”
Copy to clipboard 
